We are responding to the review by Drs Albers and Amarenco about the use of clopidogrel
plus aspirin for patients with cerebrovascular disease. 1 We view the results of the …

Background It remains unclear whether clopidogrel is better suited than aspirin as the long-
term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous …

Objectives Whether clopidogrel should be added to aspirin for stroke prevention remained
controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to …

Clopidogrel has been recently approved for treatment of non–ST-elevation acute coronary
syndromes based on the Clopidogrel in Unstable Angina to Prevent Recurrent Events …

Aims: New P2Y12 receptor inhibitors have provided new and more potent antiplatelet
strategies, although raising several concerns on possible increase of bleedings. The aim of …

Dual antiplatelet therapy with aspirin and clopidogrel is a well-established standard of care
for patients with acute coronary syndromes. Whether there are other drug strategies or …

Aims Antithrombotic secondary prevention in stable cardiovascular disease (SCVD) patients
at high ischemic risk remains unclear. We compared the efficacy and safety of aspirin …

Objectives: We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to
one year after an acute coronary syndrome (ACS) without ST-segment elevation …

Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary
syndromes (ACS). However, dual antiplatelet therapy reduces the risk of stent thrombosis …

Several therapeutic approaches have been developed to improve the outcome among
patients with acute coronary syndrome (ACS). However, treatment with antithrombotic …